{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:12:13Z","timestamp":1789387933562,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.amjmed.2004.03.024","type":"journal-article","created":{"date-parts":[[2004,8,26]],"date-time":"2004-08-26T15:14:48Z","timestamp":1093533288000},"page":"344-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Hepatitis C treatment update"],"prefix":"10.1016","volume":"117","author":[{"given":"Brian L.","family":"Pearlman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib1","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360705","article-title":"The burden of hepatitis C in the U.S.","volume":"36","author":"Kim","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib2","unstructured":"United Network for Organ Sharing. Organ procurement and transplant network. Transplants by diagnosis: January 1991 to November 2001. Available at: http:\/\/www.unos.org. Accessed March 1, 2002."},{"key":"10.1016\/j.amjmed.2004.03.024_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hep.1840210243","article-title":"Variability of hepatitis C virus","volume":"21","author":"Simmonds","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib5","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib6","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360705","article-title":"The burden of hepatitis C in the U.S.","volume":"36","author":"Kim","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510280430","article-title":"Ten year follow-up after interferon-alpha therapy for chronic hepatitis C","volume":"28","author":"Lau","year":"1998","journal-title":"Hepatology"},{"issue":"5 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib8","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1002\/hep.1840360715","article-title":"Introduction to therapy of hepatitis C","volume":"36","author":"Linday","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/hupa.2001.28228","article-title":"Hepatitis activity is a key factor in determining the natural history of chronic hepatitis C","volume":"32","author":"Fontaine","year":"2001","journal-title":"Hum Pathol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00004836-200203000-00015","article-title":"A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection","volume":"34","author":"Muir","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.7326\/0003-4819-136-4-200202190-00008","article-title":"Surprisingly small effect of antiviral treatment in patients with hepatitis C","volume":"136","author":"Falck-Ytter","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib12","first-page":"135","article-title":"Diagnosis and 10-year follow-up of a community-based hepatitis C cohort","volume":"51","author":"Yawn","year":"2002","journal-title":"J Fam Pract"},{"key":"10.1016\/j.amjmed.2004.03.024_bib13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N Engl J Med"},{"issue":"3 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib14","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1002\/hep.510260715","article-title":"Therapy of hepatitis C","volume":"26","author":"Carithers","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib15","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib16","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2004.03.024_bib17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11894-001-0038-z","article-title":"Pegylated interferons","volume":"3","author":"Shiffman","year":"2001","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.amjmed.2004.03.024_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2004.03.024_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1572-0241.2003.07537.x","article-title":"HLA class I B44 is associated with sustained response to interferon plus ribavirin therapy in patients with chronic hepatitis","volume":"98","author":"Romero-Gomez","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-one infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib24","unstructured":"Jacobson I, Brown R, Afdhal N, et al. Effect of weight-based ribavirin dosing on hematologic parameters: preliminary data from WIN-R. Proceedings of Digestive Disease Week; May 11\u201314, 2002; San Francisco, California."},{"key":"10.1016\/j.amjmed.2004.03.024_bib25","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1053\/gast.2002.1232082","article-title":"National Institutes of Health Consensus Development Conference Statement","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib26","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1111\/j.1572-0241.2003.t01-1-08735.x","article-title":"Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2a plus ribavirin for the initial treatment of chronic hepatitis C","volume":"98","author":"Wong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib27","first-page":"57","article-title":"Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C","volume":"19","author":"McHutchison","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.amjmed.2004.03.024_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1046\/j.1365-2036.2002.01265.x","article-title":"Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C","volume":"16","author":"Kraus","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjmed.2004.03.024_bib29","first-page":"2491","article-title":"Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa","volume":"98","author":"Dieterich","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.1840150504","article-title":"Interferon-alpha in acute posttransfusion hepatitis C","volume":"15","author":"Viladomiu","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.1840190105","article-title":"A multicenter randomized controlled trial of recombinant interferon alfa-2b in patients with acute transfusion-associated hepatitis C","volume":"19","author":"Lampertico","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.510290311","article-title":"Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection","volume":"29","author":"Villano","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load","volume":"37","author":"Hofer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib38","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/hep.20266","article-title":"Pegylated interferon alpha therapy in acute hepatitis C","volume":"39","author":"Kamal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage live disease in patients with human immunodeficiency virus infections","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.03.024_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1086\/321819","article-title":"Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infections","volume":"33","author":"Monga","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.03.024_bib41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2004.03.024_bib44","unstructured":"Gonzalez-Garcia J, Guerra L. Coinfection by HIV and hepatitis A, B and C virus in adult patients. Review and GESIDA\/PNS recommendations. Practice Guidelines for the Management of HIV Infection 2000\u20132002;157:157\u2013205. Available at: http:\/\/www.gesidaseimc.com\/english. Accessed June 16, 2003."},{"key":"10.1016\/j.amjmed.2004.03.024_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002030-200401020-00001","article-title":"Care of patients with hepatitis C and HIV coinfection","volume":"18","author":"Soriano","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.amjmed.2004.03.024_bib46","first-page":"344","article-title":"Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy","volume":"13","author":"Butt","year":"2003","journal-title":"AIDS Reader"},{"key":"10.1016\/j.amjmed.2004.03.024_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2004.03.024_bib48","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFN-alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients","volume":"17","author":"Perez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.amjmed.2004.03.024_bib49","doi-asserted-by":"crossref","unstructured":"Chung R, Anderson J, Volberding P, et al. A randomized, controlled trial of PEG-interferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-coinfected persons: follow-up results of ACTG A5071. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; February 8\u201311, 2004; San Francisco, California.","DOI":"10.1056\/NEJMoa032653"},{"key":"10.1016\/j.amjmed.2004.03.024_bib50","unstructured":"Torriani FJ, Rockstroh J, Rodriguez-Torres B, et al. Final results of APRICOT: a randomized, partially blinded international trial evaluating peginterferon alfa-2a and ribavirin versus interferon alfa-2a plus ribavirin in the treatment of HCV in HIV\/HCV coinfection. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; February 8\u201311, 2004; San Francisco, California. Abstract 112."},{"key":"10.1016\/j.amjmed.2004.03.024_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2004.03.024_bib52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/gut.44.6.874","article-title":"Clinical course and risk factors of hepatitis C virus related liver disease in the general population","volume":"44","author":"Bellentani","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2004.03.024_bib53","first-page":"1374","article-title":"Interferon therapy for chronic hepatitis C in habitual drinkers","volume":"91","author":"Ohnishi","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib54","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3109\/00365529409094883","article-title":"Efficacy of interferon therapy in patients with chronic hepatitis C","volume":"29","author":"Okazaki","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/alcalc\/35.3.296","article-title":"Drinking habits of subjects with hepatitis C virus-related chronic liver disease","volume":"35","author":"Loguercio","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/jhep.2003.50295","article-title":"Alcohol potentiates hepatitis C virus replicon expression","volume":"38","author":"Zhang","year":"2003","journal-title":"Hepatology"},{"issue":"5 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib57","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1002\/hep.1840360728","article-title":"Alcohol use and hepatitis C","volume":"36","author":"Peters","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib58","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib59","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib60","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0016-5085(00)70145-4","article-title":"Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels","volume":"118","author":"Persico","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib61","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1572-0241.2003.07539.x","article-title":"Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT","volume":"98","author":"Kyrlagkitsis","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib62","first-page":"1788","article-title":"Chronic hepatitis C with normal aminotransferase levels","volume":"92","author":"Gholson","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2004.03.024_bib63","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.510270333","article-title":"Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity","volume":"27","author":"Mathurin","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib65","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.510270505","article-title":"Factors associated with serum alanine transaminase activity in healthy subjects","volume":"27","author":"Piton","year":"1998","journal-title":"Hepatology"},{"issue":"3 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib66","first-page":"2S","article-title":"National Institutes of Health Consensus Development Panel Statement","volume":"26","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/jhep.2000.9321","article-title":"The significance of baseline serum alanine aminotransferases on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C","volume":"32","author":"Gordon","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2893.2001.00286.x","article-title":"Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values","volume":"8","author":"Lee","year":"2001","journal-title":"J Viral Hepat"},{"issue":"4 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib69","doi-asserted-by":"crossref","first-page":"208A","DOI":"10.1016\/S0270-9139(03)80149-0","article-title":"International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a and ribavirin","volume":"38","author":"Zeuzem","year":"2003","journal-title":"Hepatology"},{"issue":"5 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib70","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/hep.1840360717","article-title":"Retreatment of patients with chronic hepatitis C","volume":"36","author":"Shiffman","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib71","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2004.03.024_bib72","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib73","unstructured":"Leevy CB, Ramaraju CP, Blatt LM. End of treatment response for pegylated-interferon plus weight-based ribavirin nonresponders retreated with interferon alfacon-1 plus weight-based ribavirin. Proceedings of the Digestive Disease Week 2004; May 15\u201320, 2004; New Orleans, Louisiana."},{"key":"10.1016\/j.amjmed.2004.03.024_bib74","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hep.510260335","article-title":"Relationship between biochemical, virological, and histological response during interferon treatment in chronic hepatitis C","volume":"26","author":"Shiffman","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib75","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0016-5085(99)70402-6","article-title":"A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia","volume":"117","author":"Shiffman","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib76","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.amjmed.2004.03.024_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.amjmed.2004.03.024_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.11.4.515","article-title":"Developments in treatment of chronic hepatitis C","volume":"11","author":"Pockros","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.amjmed.2004.03.024_bib79","unstructured":"Davis G, Balan V, Sulkowski MS, et al. A phase I study to evaluate the pharmacokinetics, safety, and tolerability of escalating doses of a novel recombinant human albumin-interferon alpha fusion protein (Albuferon\u2122) in subjects with chronic hepatitis C. Hepatology. 2002;(4 suppl 2):285A."},{"key":"10.1016\/j.amjmed.2004.03.024_bib80","unstructured":"Hepatitis C treatments in current clinical development. Available at: http:\/\/www.hcvadvocate.org\/hcvdrugs.htm. Accessed January 2, 2004."},{"key":"10.1016\/j.amjmed.2004.03.024_bib81","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.03.024_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"issue":"4 suppl 2","key":"10.1016\/j.amjmed.2004.03.024_bib83","first-page":"304A","article-title":"First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype","volume":"36","author":"Hinrichsen","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib84","unstructured":"Nelson M. New data on BILN 2061, experimental HCV protease inhibitor. Available at: http:\/\/hivandhepatitis.com\/2004icr\/hepdart_2003\/docs\/011404_a.htm. Last accessed February 2, 2004."},{"issue":"4 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib85","doi-asserted-by":"crossref","first-page":"624A","DOI":"10.1016\/S0270-9139(03)81010-8","article-title":"VX-950","volume":"38","author":"Perni","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib86","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1128\/AAC.47.8.2674-2681.2003","article-title":"Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C","volume":"47","author":"Zhong","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.amjmed.2004.03.024_bib87","doi-asserted-by":"crossref","first-page":"38322","DOI":"10.1074\/jbc.M205566200","article-title":"Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase","volume":"277","author":"Dhanak","year":"2002","journal-title":"J Biol Chem"},{"issue":"4 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib88","doi-asserted-by":"crossref","first-page":"306A","DOI":"10.1016\/S0270-9139(03)80355-5","article-title":"Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks","volume":"38","author":"Gordon","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib89","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1089\/107999099313073","article-title":"Histamine protects T cells and natural killer cells against oxidative stress","volume":"19","author":"Hansson","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.amjmed.2004.03.024_bib90","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2893.2002.00378.x","article-title":"A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon alpha-2b for the treatment of chronic hepatitis C","volume":"9","author":"Lurie","year":"2002","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.amjmed.2004.03.024_bib91","first-page":"698","article-title":"Thymosin alpha 1","volume":"3","author":"Billich","year":"2002","journal-title":"Current Opin Investig Drugs"},{"key":"10.1016\/j.amjmed.2004.03.024_bib92","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2741\/reeves","article-title":"Activation of hepatic stellate cells","volume":"7","author":"Reeves","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.amjmed.2004.03.024_bib93","unstructured":"Hepatitis C treatments in current clinical development. Available at: http:\/\/hcvadvocate.org\/hepatitis\/hepc\/HCVDrugs.html. Accessed February 20, 2004."},{"key":"10.1016\/j.amjmed.2004.03.024_bib94","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Garcia","year":"2002","journal-title":"J Hepatol"},{"issue":"4 suppl 1","key":"10.1016\/j.amjmed.2004.03.024_bib95","doi-asserted-by":"crossref","first-page":"308A","DOI":"10.1016\/S0270-9139(03)80357-9","article-title":"A pilot study of a novel anti-inflammatory and anti-fibrotic agent, pirfenidone, in patients with liver cirrhosis","volume":"38","author":"Armendariz-Borunda","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2004.03.024_bib96","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/gast.1997.v113.pm9322499","article-title":"A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C","volume":"113","author":"Houglum","year":"1997","journal-title":"Gastroenterology"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304003407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934304003407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:30:20Z","timestamp":1757579420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934304003407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0002934304003407"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.03.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C treatment update","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2004.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}